Last reviewed · How we verify
NCT00066651
Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing
Phase 1 trial testing SS1(dsFv)-PE38 immunotoxin in Cervical Cancer. Completed.
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 July 2003 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- SS1(dsFv)-PE38 immunotoxin — full drug profile →
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
- Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
National Cancer Institute (NCI)
Who can join
18 and older, any sex, with Cervical Cancer or Fallopian Tube Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors. PURPOSE: This phase I trial is studying the side effects and best dose of immunotoxin therapy in treating patients with recurrent unresectable advanced solid tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Morello A, Sadelain M, Adusumilli PS. · · 2016 · cited 402× · PMID 26503962 · DOI 10.1158/2159-8290.cd-15-0583 -
Mesothelin as a biomarker for targeted therapy.
Lv J, Li P, Li P. · · 2019 · cited 101× · PMID 31463062 · DOI 10.1186/s40364-019-0169-8 -
Engineered antibody fusion proteins for targeted disease therapy.
Silver AB, Leonard EK, Gould JR, Spangler JB. · · 2021 · cited 40× · PMID 34706833 · DOI 10.1016/j.tips.2021.09.009 -
Amatuximab and novel agents targeting mesothelin for solid tumors.
Baldo P, Cecco S. · · 2017 · cited 30× · PMID 29184420 · DOI 10.2147/ott.s145105 -
Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
Yeo D, Castelletti L, van Zandwijk N, Rasko JEJ. · · 2021 · cited 26× · PMID 34439085 · DOI 10.3390/cancers13163932 -
Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma.
Shen J, Sun X, Zhou J. · · 2020 · cited 21× · PMID 32983962 · DOI 10.3389/fonc.2020.01263 -
The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets.
Giordano G, Ferioli E, Tafuni A. · · 2022 · cited 17× · PMID 35565412 · DOI 10.3390/cancers14092283 -
A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR, Vallera DA, Ettestad B, Hallstrom C, et al · · 2023 · cited 16× · PMID 36911670 · DOI 10.3389/fimmu.2023.1060905
Verify or expand the search:
- PubMed search for NCT00066651
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00066651 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 29 April 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00066651.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing